Nov 2026· American Journal of Epidemiology· 0 citations
Medicine
TL;DR
A marginal effects framework to generate adjusted cumulative incidence curves that are coherent with the analysis model, anchored in absolute risk estimates, and adaptable to competing risks and clustered data is described.
Abstract
The Cox regression model is the most widely used method in survival analysis, but the hazard ratio has limited clinical interpretability. Survival or cumulative incidence curves are often used to illustrate treatment effects, yet there is no consensus on the most appropriate methods for generating these curves, particularly in the presence of confounding and competing risks. We reviewed original research articles published in a general medical journal in 2025, identified limitations in common practices, and describe a marginal effects framework to generate adjusted cumulative incidence curves that are coherent with the analysis model, anchored in absolute risk estimates, and adaptable to competing risks and clustered data. The framework targets the population-average difference in cumulative incidence between exposure groups, under the assumptions of no unmeasured confounding, positivity, and non-informative censoring. As a demonstration, we applied the framework to real-world data from Yek et al. (2025) and showed that it produced clinically interpretable estimates of hospital-acquired antimicrobial resistance risk that a single hazard ratio could not convey. To facilitate implementation, we describe each analytic step in detail, discuss available software, and share an R program with core routines written in C for computational efficiency.
Conditional proportional hazard Cox regression models are routinely used in the analysis of time-to-event outcomes, with the association between one variable of interest and the outcome commonly reported as a hazard ratio (HR). However, the interpretation of HRs is strongly dependent on the underlying assumptions of th...
Pablo Martinez-Camblor, Todd A. MacKenzie, Jesse A. Columbo et al.· Journal of Biopharmaceutical...· 0 citations
The hazard ratio is the most commonly reported measure in survival analysis, yet it suffers from well-documented limitations, including non-collapsibility and susceptibility to selection bias as treatment-specific risk sets change over time. In this article, we revisit the survival ratio and the cumulative incidence ra...
Rui-Xuan Zhao, Jing-Xin Yan, Xiao-Chuan Shi et al.· 0 citations
Novel methods to broaden the scope of landmark analysis by directly modeling the restricted residual mean survival time (RRMST) at each landmark date while accommodating dependent censoring are proposed.
Yuan Zhang, D. Schaubel· Lifetime Data Analysis· 0 citations
Meta-analyses of survival outcomes commonly pool log hazard ratios or survival probabilities at selected time points. When reporting formats and observation times differ across studies, methods are needed to use available survival information for estimation at a common target time. We propose a functional random-effect...
Doubly robust survival estimators require nuisance models that the available information can support. We examine design and estimator dependence in TCGA breast cancer data. Treatment indicators disagree for 337 of 1076 patients; 67.4% have unobserved five-year binary outcomes; and receptor imputation expands the triple...
W. Fahmy, E. Krikun, A. Al Khateeb· medRxiv· 0 citations
Clinical trials are usually analyzed using frequentist methods and interpreted through p-values, which are often poorly understood. In contrast, Bayesian analyses yield probabilistic statements that offer a more intuitive interpretation of treatment effects and uncertainty.
To demonstrate the utility of pr...
G. Siontis, K. Chalkou, T. Perneger et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.